Skip to main content

Bleeding Disorder Testing Market Size to Surpass USD 149.6 Million by 2029, exhibiting a CAGR of 7.8%

As per the report by Fortune Business Insights, The Global Bleeding Disorder Testing Market size is projected to reach USD 149.6 Million by 2029, at a CAGR of 7.8% during the forecast period.

Bleeding Disorder Testing Market

Bleeding Disorder Testing Market (2022-2029)
Bleeding Disorder Testing Market (2022-2029)

Pune, India, Sept. 13, 2023 (GLOBE NEWSWIRE) — The global bleeding disorder testing market size was valued at USD 88.5 million in 2022 and it is expected to reach USD 149.6 million by 2029, exhibiting a CAGR of 7.8% during the forecast period. The surging prevalence of bleeding disorders such as Von Willebrand disease, haemophilia A, hemophilia B, and others are driving the growth.

Fortune Business Insights™ provide this information in its research report, titled “Bleeding Disorder Testing Market, 2022-2029”.

Key Industry Development:

July 2022 – HORIBA, Ltd. launched new products in its Yumizen H500 and H550 haematology product family with enhanced performance, new features, and increased benefits.

Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bleeding-disorder-testing-market-106908


Key Takeaways:

  • According to the National Hemophilia Foundation, Von Willebrand disease, which affects up to 1% of Americans or 1 in every 100 persons, is the most prevalent bleeding illness.
  • Eight new configurations for Cobas pro integrated solutions were released by F. Hoffmann-La Roche Ltd. with the goal of maximizing throughput and improving testing effectiveness.
  • In collaboration with a major biopharmaceutical business, rHEALTH created a fingerstick-based method for measuring thrombocytopenia (low platelet counts).
  • In the Yumizen H500 and H550 hematology product line, HORIBA Medical has introduced new products with improved performance, fresh features, and expanded advantages.


Discover the Leading Players Featured in the Report:

Major players in the bleeding disorder testing market are F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthcare GmbH (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), Abbott (U.S.), Thermo Fisher Scientific Inc. (U.S.)


Report Scope

Report CoverageDetails
Forecast Period2022 to 2029
Forecast Period 2022 to 2029 CAGR7.8%
2029 Value ProjectionUSD 149.6 Million
Base Year2021
Market Size in 2022USD 88.5 Million
Historical Data for2018 to 2020
No. of Pages130


Browse Complete Report Details: https://www.fortunebusinessinsights.com/bleeding-disorder-testing-market-106908


Drivers and Restraints:

Market Value to Rise on Account of Growing Prevalence and Diagnosis of Bleeding Disorder

The bleeding disorder testing market growth can be attributed to the escalating prevalence of various disorders in emerging and developed regions. These include idiopathic thrombocytopenic purpura, hemophilia A, hemophilia B, and others.

However, the market growth could be hindered by the low penetration of testing in emerging countries and low adherence to guidelines.


Market Segments:

Reagents & Consumables Segment to Register Lucrative Growth Due to Rising Incidence of Bleeding Disorder

Based on product type, the market is fragmented into instruments and reagents & consumables. The reagents & consumables segment is estimated to record substantial growth considering the soaring rate of testing driven by healthcare access in emerging regions.

Hemophilia A Segment Share to Rise Owing to Growing Disease Prevalence

On the basis of indication, the market for bleeding disorder testing is segmented into hemophilia A, idiopathic thrombocytopenic purpura, Von Willebrand disease, hemophilia B, and others. The hemophilia A segment is estimated to record considerable growth over the forecast period. The upsurge can be credited to the surging prevalence of bleeding disorders.

Hospitals & Clinics Segment to Record Commendable Surge Due to Escalating Rate of Disease Diagnosis

Based on end-user, the market is subdivided into diagnostic centres, hospitals & clinics, and others. The diagnostic centres segment is anticipated to record notable growth over the estimated period. The escalation can be credited to the growing number of portable analyzers and surging technological advancements.

Citing the regional landscape, the market is classified into Europe, North America, Asia Pacific, and the rest of the world.


Quick Buy – Bleeding Disorder Testing Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/106908


By Product Type

  • Reagents & Consumables
  • Instruments

By Indication

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Idiopathic Thrombocytopenic Purpura
  • Others

By End-user

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
  • Rest of the World


Report Coverage:

The report provides an overview of the significant factors that are expected to impel the business landscape across various regions. It further gives an insight into the major steps taken by leading industry participants for propelling the business scenario throughout the forecast period. These insights have been provided after extensive research and data collation from credible sources.       


Ask For Customization: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/bleeding-disorder-testing-market-106908


Regional Insights:

The Europe bleeding disorder testing market share is set to be impelled by the growing prevalence of disorders in Germany, the U.K., and other countries. Additional factors favouring industry expansion comprise the escalating adherence to guidelines and the growing patient population.

The North America market is estimated to register appreciable expansion over the forecast period. The rise can be credited to the growing launch of testing instruments and the escalating number of regulatory approvals.


Competitive Landscape:

Market Players to Enter into Partnership Deals to Maintain Industry Position

Leading bleeding disorder testing companies are focused on the adoption of strategic initiatives such as the formation of alliances, acquisitions, mergers, and others. These steps are being taken for the consolidation of market position. Some of the additional initiatives include growing participation in trade conferences.


FAQ’s

How big is the Bleeding Disorder Testing Market?

Bleeding Disorder Testing Market size was USD 88.5 Million in 2022.

How fast is the Bleeding Disorder Testing Market growing?

The Bleeding Disorder Testing Market will exhibit a CAGR of 7.8% during the forecast period, 2018-2029


Related Reports:

Immunodiagnostics Market Share, Size, Trends and Forecast 2020-2025

Hematology Analyzers and Reagents Market Size, Share, Trends, Growth | Global Forecast Report 2030

Breast Pump Market Size, Share| Global Forecast Report 2029

Liquid Biopsy Market Trends, Growth | Global Forecast Report 2030


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

Contact Us:

Fortune Business Insights Pvt. Ltd.
9th Floor, Icon Tower, Baner – Mahalunge Road,

Baner, Pune-411045,

Maharashtra, India.

Phone:

US:+1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.